The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 1, 2012, Pages 96-101

  Zai, Gwyneth C M ^a,b   Zai, Clement C H ^a,b   Chowdhury, Nabilah I ^a   Tiwari, Arun K ^a   Souza, Renan P ^c   Lieberman, Jeffrey A ^d   Meltzer, Herbert Y ^e   Potkin, Steven G ^f   Müller, Daniel J ^a   Kennedy, James L ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotic response; Antipsychotic induced weight gain; Brain derived neurotrophic factor (BDNF); Pharmacogenetics; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; BDNF GENE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GENE; GENE ACTIVITY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CLINICAL TRIALS AS TOPIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84864510413     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.05.014     Document Type: Article

References (61)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington, DC, (DSM-IV). 4th ed.
2. Anttila S., Illi A., Kampman O., Mattila K.M., Lehtimaki T., Leinonen E. Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics. J Neural Transm 2005, 112(7):885-890.
3. Arnold S.E. Neurodevelopmental abnormalities in schizophrenia: insights from neuropathology. Dev Psychopathol 1999, 11(3):439-456.
4. Arranz M.J., de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007, 12(8):707-747.
5. Baquet Z.C., Bickford P.C., Jones K.R. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci 2005, 25(26):6251-6259.
6. Beckers S., Peeters A., Zegers D., Mertens I., Van Gaal L., Van Hul W. Association of the BDNF Val66Met variation with obesity in women. Mol Genet Metab 2008, 95(1-2):110-112.
7. Chen Z.Y., Patel P.D., Sant G., Meng C.X., Teng K.K., Hempstead B.L., et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 2004, 24(18):4401-4411.
8. Chiaruttini C., Vicario A., Li Z., Baj G., Braiuca P., Wu Y., et al. Dendritic trafficking of BDNF mRNA is mediated by translin and blocked by the G196A (Val66Met) mutation. Proc Natl Acad Sci U S A 2009, 106(38):16481-16486.
9. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003, 25(2):115-121.
10. Duman R.S. Synaptic plasticity and mood disorders. Mol Psychiatry 2002, 7(Suppl. 1):S29-S34.
11. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112(2):257-269.
12. Endicott J. Good diagnoses require good diagnosticians: collecting and integrating the data. Am J Med Genet 2001, 105(1):48-49.
13. Fatemi S.H., Folsom T.D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 2009, 35(3):528-548.
14. First M.B., Gibbon M., Spitzer R.L., Williams J.B.W. Structured Clinical Interview for DSM-IV axis I disorders-Research Version (SCID-I/P, version 2.0, February, Final Version) 1996, American Psychiatric Press, Washington, DC.
15. Gauderman W., Morrison J. QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies http://hydrauscedu/gxe.
16. Gebhardt S., Theisen F.M., Haberhausen M., Heinzel-Gutenbrunner M., Wehmeier P.M., Krieg J.C., et al. Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. J Clin Pharm Ther 2010, 35(2):207-211.
17. Geiger B.M., Haburcak M., Avena N.M., Moyer M.C., Hoebel B.G., Pothos E.N. Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity. Neuroscience 2009, 159(4):1193-1199.
18. Gratacos M., Gonzalez J.R., Mercader J.M., de Cid R., Urretavizcaya M., Estivill X. Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry 2007, 61(7):911-922.
19. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001, 411(6833):86-89.
20. Hanson I.M., Seawright A., van Heyningen V. The human BDNF gene maps between FSHB and HVBS1 at the boundary of 11p13-p14. Genomics 1992, 13(4):1331-1333.
21. Hofer M.M., Barde Y.A. Brain-derived neurotrophic factor prevents neuronal death in vivo. Nature 1988, 331(6153):261-262.
22. Hong C.J., Yu Y.W., Lin C.H., Tsai S.J. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci Lett 2003, 349(3):206-208.
23. Hwang R., Zai C., Tiwari A., Muller D.J., Arranz M.J., Morris A.G., et al. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J 2010, 10(3):200-218.
24. Hwang R., Souza R.P., Tiwari A.K., Zai C.C., Muller D.J., Potkin S.G., et al. Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. Pharmacogenomics 2011, 12(2):277-291.
25. Jindal R.D., Pillai A.K., Mahadik S.P., Eklund K., Montrose D.M., Keshavan M.S. Decreased BDNF in patients with antipsychotic naive first episode schizophrenia. Schizophr Res 2010, 119(1-3):47-51.
26. Johnson P.M., Kenny P.J. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci 2010, 13(5):635-641.
27. Jones K.R., Reichardt L.F. Molecular cloning of a human gene that is a member of the nerve growth factor family. Proc Natl Acad Sci U S A 1990, 87(20):8060-8064.
28. Kane J.M., Honigfeld G., Singer J., Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 1988, 24(1):62-67.
29. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13(2):261-276.
30. Kluge M., Schuld A., Himmerich H., Dalal M., Schacht A., Wehmeier P.M., et al. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol 2007, 27(6):662-666.
31. Krebs M.O., Guillin O., Bourdell M.C., Schwartz J.C., Olie J.P., Poirier M.F., et al. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry 2000, 5(5):558-562.
32. Lahiri D.K., Nurnberger J.I. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991, 19(19):5444.
33. Lee J.G., Cho H.Y., Park S.W., Seo M.K., Kim Y.H. Effects of olanzapine on brain-derived neurotrophic factor gene promoter activity in SH-SY5Y neuroblastoma cells. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(6):1001-1006.
34. Lencz T., Robinson D.G., Napolitano B., Sevy S., Kane J.M., Goldman D., et al. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics 2010, 20(9):569-572.
35. Lett T.A., Wallace T.J., Chowdhury N.I., Tiwari A.K., Kennedy J.L., Muller D.J. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 2012, 17(3):242-266.
36. Li J., Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb) 2005, 95(3):221-227.
37. Lyons W.E., Mamounas L.A., Ricaurte G.A., Coppola V., Reid S.W., Bora S.H., et al. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A 1999, 96(26):15239-15244.
38. Masellis M., Basile V., Meltzer H.Y., Lieberman J.A., Sevy S., Macciardi F.M., et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998, 19(2):123-132.
39. McGue M., Gottesman I.I. The genetic epidemiology of schizophrenia and the design of linkage studies. Eur Arch Psychiatry Clin Neurosci 1991, 240(3):174-181.
40. Muller D.J., Kennedy J.L. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006, 7(6):863-887.
41. Muller D.J., Zai C.C., Sicard M., Remington E., Souza R.P., Tiwari A.K., et al. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J 2012, 12(2):156-164.
42. Nathan P.J., O'Neill B.V., Mogg K., Bradley B.P., Beaver J., Bani M., et al. The effects of the dopamine D3 receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects. Int J Neuropsychopharmacol 2010, 1-13.
43. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol Rep 1962, 10:799-812.
44. Park S.W., Seo M.K., Cho H.Y., Lee J.G., Lee B.J., Seol W., et al. Differential effects of amisulpride and haloperidol on dopamine D2 receptor-mediated signaling in SH-SY5Y cells. Neuropharmacology 2011, 61(4):761-769.
45. Park S.W., Phuong V.T., Lee C.H., Lee J.G., Seo M.K., Cho H.Y., et al. Effects of antipsychotic drugs on BDNF, GSK-3beta, and beta-catenin expression in rats subjected to immobilization stress. Neurosci Res 2011, 71(4):335-340.
46. Pelleymounter M.A., Cullen M.J., Wellman C.L. Characteristics of BDNF-induced weight loss. Exp Neurol 1995, 131(2):229-238.
47. Petryshen T.L., Sabeti P.C., Aldinger K.A., Fry B., Fan J.B., Schaffner S.F., et al. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol Psychiatry 2010, 15(8):810-815.
48. Rios M., Fan G., Fekete C., Kelly J., Bates B., Kuehn R., et al. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol Endocrinol 2001, 15(10):1748-1757.
49. Sicard M.N., Zai C.C., Tiwari A.K., Souza R.P., Meltzer H.Y., Lieberman J.A., et al. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics 2010, 11(11):1561-1571.
50. Skledar M., Nikolac M., Dodig-Curkovic K., Curkovic M., Borovecki F., Pivac N. Association between brain-derived neurotrophic factor Val66Met and obesity in children and adolescents. Prog Neuropsychopharmacol Biol Psychiatry 2012, 36(1):136-140.
51. Strange P.G. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 2001, 53(1):119-133.
52. Studer L., Spenger C., Seiler R.W., Altar C.A., Lindsay R.M., Hyman C. Comparison of the effects of the neurotrophins on the morphological structure of dopaminergic neurons in cultures of rat substantia nigra. Eur J Neurosci 1995, 7(2):223-233.
53. Tsai A., Liou Y.J., Hong C.J., Wu C.L., Tsai S.J., Bai Y.M. Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment. Neuromolecular Med 2011, 13(4):328-333.
54. Tyler W.J., Alonso M., Bramham C.R., Pozzo-Miller L.D. From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning. Learn Mem 2002, 9(5):224-237.
55. Vojvoda D., Grimmell K., Sernyak M., Mazure C.M. Monozygotic twins concordant for response to clozapine. Lancet 1996, 347(8993):61.
56. Volavka J., Czobor P., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J.P., et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002, 159(2):255-262.
57. Zai C.C., Tiwari A.K., De Luca V., Muller D.J., Bulgin N., Hwang R., et al. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur Neuropsychopharmacol 2009, 19(5):317-328.
58. Zai C.C., Manchia M., De Luca V., Tiwari A.K., Squassina A., Zai G.C., et al. Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched case-control and family based study designs. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(8):1412-1418.
59. Zhang X.Y., Zhou D.F., Wu G.Y., Cao L.Y., Tan Y.L., Haile C.N., et al. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 2008, 33(9):2200-2205.
60. Zhang J.P., Lencz T., Malhotra A.K. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010, 167(7):763-772.
61. Zhou J., Bradford H.F., Stern G.M. The stimulatory effect of brain-derived neurotrophic factor on dopaminergic phenotype expression of embryonic rat cortical neurons in vitro. Brain Res Dev Brain Res 1994, 81(2):318-324.